louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00173147: Morphology of the VMO in Patients With PFPS and Healthy Young Adults--A Sonographic Study
Official title: Morphology of the Vastus Medialis Obliquus in Patients With Patellofemoral Pain Syndrome and Healthy Young Adults --A Sonographic Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patellofemoral Pain Syndrome
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-15
Sex: ALL
Minimum age (years): 15
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Time perspective: RETROSPECTIVE

Brief summary: Background：Patellofemoral pain syndrome（PFPS） is a common knee disorder characterized by anterior or retropatellar pain associated with activities that load the patellofemoral joint. Previous studies reveal that the vastus medialis obliquus（VMO） is an important dynamic medial stabilizer of the patellar. Insufficiency of the VMO leads to lateral shift of the patella and the increases the patellofemoral contact force. An in vitro study conducted by Hubbard JK. et al. claimed that there were no significant relationship between several morphologic characteristics of the VMO and the extent of patellofemoral joint deterioration. We consider that the condition might be different in vivo, so we chose ultrasonogrphy as the measurement tool to examine the morphology of the VMO in PFPS patients and healthy controls. Purpose：To determine if there are significant differences in several morphologic parameters of the VMO between patients with PFPS and healthy controls under 50. Method：31 PFPS patients and 31 matched healthy adults under 50 were recruited for the study. The HDI 5000 ultrasonography machine was used to evaluate morphologic parameters of the VMO, including the percent of patella attachment, fiber angle, the volume attached to the patella, and the change of shape of the VMO.


Eligibility criteria: Inclusion Criteria:

1. under 50 years old.
2. Have a diagnosis of PFPS.

Exclusion Criteria:

1. Diagnosis other than PFPS，such as meniscal lesion, ligamentous instability ,patellar tendon pathology, traction apophysitis, radiation pain, referred pain, ect.
2. Knee operation within three month.
3. X-ray findings (1)joint space narrowing (2)osteophyte formation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: NTUH
Study officials:
affiliation: NTU department of physical therapy
name: Mei-Hwa Jan, Master
role: STUDY_CHAIR
References:
Clinical trial NCT01196377: Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study
Official title: Personalized Medicine, Biomarker-based Study of Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Asthma
Keywords: Asthma
Acute asthma
Pediatrics
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2010-09-08
Enrollment: 16
Sex: ALL
Minimum age (years): 5
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Our overall objective is to model a pediatric Acute Asthma Clinical Decision Rule (ADR) for personalized medicine by identification of treatment-response phenotypes that are important determinants of outcome. The Specific Aim of this study is to determine the feasibility of this approach by enrolling a pilot cohort of 16 participants in this DBRCT of 4 different albuterol treatment regimens, 2 of which will use 10mg/hr and 2 of which will use 25mg/hr. Within these dosages there will be a pulsed-treatment regimen and a continuous regimen.

Detailed description: The objective of this study is to determine the feasibility of this approach by enrolling a pilot cohort of 16 participants in this DBRCT of 4 different albuterol treatment regimens, 2 of which will use 10mg/hr and 2 of which will use 25mg/hr. Participants are randomized in randomly permuted blocks of four. Within these dosages there will be a pulsed-treatment regimen and a continuous regimen.

Eligibility criteria: Inclusion Criteria:

* Doctor diagnosed asthma
* Acute asthma exacerbation
* Treatment with systemic corticosteroids and nebulized albuterol
* Ages 5 to 17 years

Exclusion Criteria:

* Other acute or chronic lung disease

Primary outcomes:
measure: %FEV1
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Vanderbilt University School of Medicine
name: Donald H Arnold, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04620577: The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice
Official title: The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2020-11-09
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with periampullary carcinoma and pancreatic head carcinoma who received PTCD drainage.

Brief summary: To investigate the influence of antibiotics on the incidence of biliary tract infections after PTCD for malignant obstructive jaundice.

Detailed description: This project designed a large-scale, single-center, prospective randomized controlled clinical trial to explore the impact of antibiotics on the incidence of biliary tract infections after PTCD with malignant obstructive jaundice. This study will provide evidence-based medical evidence for the need for routine use of antibiotics to prevent biliary tract infections after PTCD with malignant obstructive jaundice, and provide references for clinicians to prevent patients from PTCD infections.

Eligibility criteria: Inclusion Criteria:

1. 18-80 years old;
2. ECOG score 0-1 before operation;
3. Patients diagnosed as pancreatic head cancer and periampullary cancer according to preoperative imaging, including ampullary cancer, extrahepatic bile duct cancer and duodenal papillary cancer;
4. Bilirubin\>200 mmol/L before PTCD , and the duration of PTCD continuous drainage \>2 weeks;
5. Volunteer to participate and sign the informed consent form;

Exclusion Criteria:

1. Decompensated liver cirrhosis, acute and chronic hepatitis and other diseases before surgery;
2. A history of other malignant tumors before surgery;
3. Duration of preoperative PTCD drainage\<2 weeks;
4. Jaundice caused by other reasons besides cancer around the ampulla and cancer of the head of the pancreas;

Primary outcomes:
measure: Incidence of patients with biliary tract infection after surgery
timeFrame: October 2020 to June 2023
Secondary outcomes:
measure: Decline rate of bilirubin in patients after PTCD
timeFrame: October 2020 to June 2023
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
state: Shanghai
Study officials:
References:
Clinical trial NCT04718077: Intraosseous vs Submucosal Injection of Dexamethasone
Official title: Effectiveness of Intraosseous Injection of Dexamethasone Following Impacted Mandibular Third Molar Removal (Randomized Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tooth, Impacted
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2021-01-22
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Thirty-eight patients were randomly divided into 2 groups; the intraosseous injection group of dexamethasone (4 mg) and the submucosal injection group. All surgeries were performed by one surgeon.

Postoperative pain was evaluated by visual analog scale score immediately after surgery and on postoperative days 1, 3, and 7.

Swelling (determined using two linear measurements) were assessed just before the surgery and on postoperative days 1, 3, and 7 by using a digital vernier caliper.

Early healing of periodontal soft tissue wound was assessed by using Early Wound Healing Score (EHS) which composed of 3 parameters: clinical signs of re-epithelization (CSR), clinical signs of hemostasis (CSH), and clinical signs of inflammation (CSI) and were assessed on postoperative days 1, 7, and 14. Mouth opening (determined by measurement of the maximum inter-incisal distance) were assessed just before the surgery and on postoperative days 1, 3, and 7 by using a digital vernier caliper.


Eligibility criteria: Inclusion criteria

* Patient complaining of impacted mandibular third molar mesioangular or horizontal, according to the Pell and Gregory classification 1933)
* Healthy patient (American society of anesthesiologists class I status)
* Patient age range from 18 to 40 years old.
* Patient without any local inflammation or pathology.
* Patient who will able to understand verbal and written instructions.

Exclusion criteria

* Pregnant or breast-feeding women.
* Patient had anti-inflammatory drugs within 2 weeks before the procedure.
* Patient under radiotherapy or chemotherapy.
* Habits (heavy smoking and alcoholic).
* Allergy to drugs used in this study.
* Patient under anticoagulant or corticosteroid therapy.

Primary outcomes:
measure: Change in mouth opening
timeFrame: baseline, 1st, 3rd, 7th days
measure: change in swelling
timeFrame: 1st, 3rd, 14th days
measure: change in pain scores
timeFrame: 1st, 3rd, 7th days
Secondary outcomes:
measure: change in early healing of periodontal soft tissue wound
timeFrame: 1st, 7th, 14th days
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University, Egypt
state: Azarita
Study officials:
References:
Clinical trial NCT02820077: Hemostatic Powder Versus Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions
Official title: Randomized Controlled Trial of Hemostatic Powder Versus Optimal Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Gastrointestinal Hemorrhage
Gastrointestinal Neoplasms
Keywords: Endoscopy, Gastrointestinal
Lead sponsor: Instituto do Cancer do Estado de São Paulo
Sponsor class: OTHER
First posted: 2016-06-30
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the efficacy of the endoscopic hemostatic powder for the treatment of bleeding from malignant lesions of the upper GI tract. Half of participants will receive hemostatic powder and half will be submitted to standard treatment.

Detailed description: Gastrointestinal tumor bleeding is a challenging clinical condition with a high mortality rate. Several endoscopic hemostasis techniques have been tested, but results were disappointing. Re-bleeding and mortality rates are still high.

Hemostatic powder is a promising therapy for tumor bleeding, since it can be applied over large surfaces. Bleeding from a tumor lesion often occurs diffusely on the surface of the tumor rather than from a specific vessel.

Eligibility criteria: Inclusion Criteria:

* Any kind of malignancy
* Gastrointestinal bleeding in the last 48 hours
* Referred to emergency endoscopy

Exclusion Criteria:

* under 18 years old
* bleeding from non malignant lesions
* previous endoscopic treatment with another method done in the last 48h

Primary outcomes:
measure: rebleeding
timeFrame: until 30 days after endoscopy
measure: mortality
timeFrame: until 30 days after endoscopy
Secondary outcomes:
measure: Successful initial hemostasis
timeFrame: From the moment of the procedure until 24 hours after it
measure: Hospital length of stay
timeFrame: from the moment of the endoscopic procedure until hospital discharge or death, whichever came first, assessed up to 100 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05583877: DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients
Official title: DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: University of Massachusetts, Worcester
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2022-10-18
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The purpose of this study is to culturally-adapt a patient-centric intervention designed to improve implementation of diabetes self-management training in Spanish-speaking patients. To accomplish cultural adaptation of the DM-BOOST intervention, a Patient Research Expert Panel (PREP) (n\</=4) will participate in Community Engagement Studios to inform adaptations (Aim 1) and usability test the intervention (Aim 2). A randomized pilot with new patients (n\</=70) will then be conducted to assess feasibility (Aim 3).
Primary purpose: SUPPORTIVE_CARE

Brief summary: The specific aims of this project are to culturally adapt the DM-BOOST intervention for Latinx patients, usability test 'DM-BOOST para Latinx' to optimize cultural appropriateness and patient engagement and conduct a feasibility evaluation of DM-BOOST para Latinx. These aims will be accomplished via a community-based participatory research approach in collaboration with clinical, community and patient partners. This project will inform subsequent proposals to evaluate implementation of DM-BOOST in the UMass Memorial Health Care system.


Eligibility criteria: Aims 1 and 2 Patient Inclusion Criteria:

* Age \> 18 years
* Diagnosis of type 2 diabetes
* Identifies as Hispanic/Latinx
* Spanish language preference

Aims 1 and 2 Patient Exclusion Criteria:

* Cognitive impairment
* Current prisoner
* Pregnant women

Aim 3 Patient Inclusion Criteria:

* Age \> 18 years
* Diagnosis of type 2 diabetes
* Identifies as Hispanic/Latinx
* Spanish language preference

Aim 3 Patient Exclusion Criteria:

* Cognitive impairment
* Current prisoner
* Pregnant women
* Completed DSMT in previous year

Primary outcomes:
measure: Process Evaluation
timeFrame: 3 - 6 months
Secondary outcomes:
measure: Diabetes self-efficacy
timeFrame: 3 months
measure: Diabetes treatment satisfaction
timeFrame: 3 months
measure: Change in HbA1c Percentage
timeFrame: 6 months
Other outcomes:
Locations:
city: Worcester
country: United States
facility: UMass Memorial health
state: Massachusetts
city: Worcester
country: United States
facility: University of Massachusetts Medical School
state: Massachusetts
Study officials:
affiliation: UMass Chan Medical School
name: Daniel J Amante, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04399577: Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
Official title: Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Warts
Lead sponsor: Zagazig University
Sponsor class: OTHER_GOV
First posted: 2020-05-22
Enrollment: 39
Sex: ALL
Minimum age (years): 9
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.

Detailed description: 39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured

Eligibility criteria: Inclusion Criteria:

* Chronic multiple cutaneous

Exclusion Criteria:

* Hypersensitivity to Candida antigen
* Fever
* Immunosuppressive disorders
* Previous wart therapy in the last month

Primary outcomes:
measure: Resolution of warts
timeFrame: 12 weeks
Secondary outcomes:
measure: Recurrence
timeFrame: 6 months
Other outcomes:
Locations:
city: Zagazig
country: Egypt
facility: Zagazig University Faculty of Medicine
state: Sharqia
Study officials:
References:
citation: Hammad NM, Abdelhadi AA, Fawzy MM, Marei A. Complement component 3c and tumor necrosis factor-alpha systemic assessment after Candida antigen immunotherapy in cutaneous warts. Braz J Microbiol. 2020 Dec;51(4):1673-1681. doi: 10.1007/s42770-020-00322-0. Epub 2020 Jun 27.
Clinical trial NCT04950777: Feasibility and Efficacy of Physical Literacy Screening Integration Into Pediatric Clinical Settings
Official title: Feasibility and Efficacy of Physical Literacy Screening Integration Into Pediatric Clinical Settings
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pediatric ALL
Motility Disorder
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
First posted: 2021-07-06
Enrollment: 200
Sex: ALL
Minimum age (years): 6
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The proposed research will be the first study to investigate the feasibility of incorporating physical literacy screening into primary care clinical settings, while determining the efficacy of integration on physical literacy. To investigate aim 1, feasibility, the research team will provide all children ages 6-11 presenting for well-child care by the participating pediatricians with physical literacy screening (PAVSPED) at point of entry for care. The child will complete the 5 yes/no screen and answers will be provided to the pediatrician for acknowledgement. To investigate aim 2, efficacy, participants will be randomized into a control group (standard of care) or an intervention group (patient education). The intervention group will receive the patient education document with their questionnaire, randomization will occur by the study team prior to subject visits. The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)). All participants will receive a 6-month follow-up email with the same 6 questions to assess if responses changed between the two groups.


Eligibility criteria: Inclusion Criteria:

* • Children 6-11 years presenting for an annual well-child appointment at Longwood Pediatrics

Exclusion Criteria:

* • Children with physical handicaps or other significant health problems that would preclude physical activity involvement.

Primary outcomes:
measure: Physical Literacy Vital Sign (PAVSped) total score.
timeFrame: Month 2-4
Secondary outcomes:
measure: Improvement on the follow-up the Physical Literacy Vital Sign (PAVSped) survey total score.
timeFrame: Month 6
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children's Hospital
state: Massachusetts
Study officials:
affiliation: Boston Children's Hospital
name: Andrea Stracciolini, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01158677: Short Term Outcome After Meniscectomy
Official title: Short Term Outcome After Meniscectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Meniscectomy
Keywords: meniscectomy
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2010-07-08
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all the meniscectomy patients (male \& female, all ages)

Brief summary: Short term outcome after meniscectomy: a meniscectomy is a very frequent performed orthopedically procedure. The short term outcome is favourable, but some patients keep having residual lesions after surgery.

This prospective study examens the clinical outcome after meniscectomy using questionnaires (KOOS, VAS, SF-36, Tegner) (before the surgery, 3, 6 \& 12 months postoperative.) The investigators will also record the further treatment options for the people at risk.


Eligibility criteria: Inclusion criteria:

* all the meniscectomy patients (male \& female, all ages)

Exclusion Criteria:None

Primary outcomes:
measure: The clinical outcome (residual lesions) after a meniscectomy
timeFrame: 12 months post-operative
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital Ghent, Belgium
name: Peter Verdonk, MD
role: PRINCIPAL_INVESTIGATOR
References: